piracetam has been researched along with Metabolic Syndrome in 1 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asadullaev, MM | 1 |
| Saidvaliev, FS | 1 |
| Shermukhamedova, FK | 1 |
| Rizvonov, ZhK | 1 |
| Vakhabova, NM | 1 |
1 trial available for piracetam and Metabolic Syndrome
| Article | Year |
|---|---|
[Assessment of multimodal effect of cytoflavin in the acute brain stroke in patients with metabolic syndrome].
Topics: Administration, Intravenous; Aged; Antioxidants; Drug Combinations; Female; Flavin Mononucleotide; H | 2012 |